{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:41:15Z","timestamp":1780422075379,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","award":["CIVP18A3935"],"award-info":[{"award-number":["CIVP18A3935"]}],"id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012638","name":"Valerion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012638","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["SAF2017-83151-R"],"award-info":[{"award-number":["SAF2017-83151-R"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["BFU2017-84345-P"],"award-info":[{"award-number":["BFU2017-84345-P"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005773","name":"Michigan Sea Grant, University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["P01 NS097197"],"award-info":[{"award-number":["P01 NS097197"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS070899"],"award-info":[{"award-number":["R01NS070899"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.yebeh.2019.106839","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T09:00:01Z","timestamp":1578646801000},"page":"106839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"PA","title":["The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic"],"prefix":"10.1016","volume":"103","author":[{"given":"Matthew S.","family":"Gentry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Afawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin D.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Delgado-Escueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. Paul","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar R.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan J.","family":"Guinovart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berge A.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascual","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn A.","family":"Worby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Serratosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2019.106839_bb0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1684\/epd.2016.0842","article-title":"Lafora disease","volume":"18","author":"Turnbull","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2019.106839_bb0010","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1074\/jbc.R117.803064","article-title":"Lafora disease offers a unique window into neuronal glycogen metabolism","volume":"293","author":"Gentry","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.yebeh.2019.106839_bb0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","article-title":"Lafora disease \u2014 from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2019.106839_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0887-8994(00)00276-9","article-title":"Lafora's disease: towards a clinical, pathologic, and molecular synthesis","volume":"25","author":"Minassian","year":"2001","journal-title":"Pediatr Neurol"},{"issue":"Suppl. 3","key":"10.1016\/j.yebeh.2019.106839_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1528-1157.1999.tb00893.x","article-title":"Idiopathic epilepsies with a complex mode of inheritance","volume":"40","author":"Serratosa","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106839_bb0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.yebeh.2017.12.015","article-title":"The 3rd International Lafora Epilepsy Workshop: evidence for a cure","volume":"81","author":"Brewer","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106839_bb0035","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.yebeh.2018.11.014","article-title":"The 4th International Lafora Epilepsy Workshop: shifting paradigms, paths to treatment, and hope for patients","volume":"90","author":"Brewer","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106839_bb0040","unstructured":"Valerion_Therapeutics, and Ionis_Pharmaceuticals. (2019) Natural history and functional status study of patients with Lafora disease. NCT03876522."},{"key":"10.1016\/j.yebeh.2019.106839_bb0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF01989438","article-title":"Uber des Vorkommen amyloider KJrperchen im innern der Ganglienzellen","volume":"205","author":"Lafora","year":"1911","journal-title":"Virchows Arch f Path Anat"},{"key":"10.1016\/j.yebeh.2019.106839_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02863929","article-title":"Beitrag zur histopathologie der myoklonischen epilepsie","volume":"6","author":"Lafora","year":"1911","journal-title":"Z Ges Neurol Psychiatr"},{"key":"10.1016\/j.yebeh.2019.106839_bb0055","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1528-1167.2008.01543.x","article-title":"The maestro don Gonzalo Rodriguez-Lafora","volume":"49","author":"Nanduri","year":"2008","journal-title":"Epilepsia"},{"issue":"Suppl","key":"10.1016\/j.yebeh.2019.106839_bb0060","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/ana.410160703","article-title":"The search for epilepsies ideal for clinical and molecular genetic studies","volume":"16","author":"Delgado-Escueta","year":"1984","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2019.106839_bb0065","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/hmg\/4.9.1657","article-title":"The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q","volume":"4","author":"Serratosa","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.yebeh.2019.106839_bb0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/2470","article-title":"Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy","volume":"20","author":"Minassian","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.yebeh.2019.106839_bb0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/hmg\/8.2.345","article-title":"A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2)","volume":"8","author":"Serratosa","year":"1999","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.yebeh.2019.106839_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ng1238","article-title":"Mutations in NHLRC1 cause progressive myoclonus epilepsy","volume":"35","author":"Chan","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.yebeh.2019.106839_bb0085","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.yebeh.2019.106839_bb0090","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.23899","article-title":"Inhibiting glycogen synthesis prevents Lafora disease in a mouse model","volume":"74","author":"Pederson","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2019.106839_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002037","article-title":"PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease","volume":"7","author":"Turnbull","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.yebeh.2019.106839_bb0100","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein depletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2019.106839_bb0105","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1021\/acs.molpharmaceut.9b00396","article-title":"Central nervous system delivery and biodistribution analysis of an antibody-enzyme fusion for the treatment of Lafora disease","volume":"16","author":"Austin","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.yebeh.2019.106839_bb0110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cmet.2019.07.002","article-title":"Targeting pathogenic Lafora bodies in Lafora disease using an antibody-enzyme fusion","volume":"30","author":"Brewer","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.yebeh.2019.106839_bb0115","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.molmed.2019.08.005","article-title":"Antibody-mediated enzyme therapeutics and applications in glycogen storage diseases","volume":"25","author":"Zhou","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.yebeh.2019.106839_bb0120","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2019.106839_bb0125","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2019.106839_bb0130","unstructured":"Valerion_Therapeutics. (2016) VAL-1221 delivered intravenously in ambulatory and ventilator-free participants with late-onset Pompe disease. NCT02898753."},{"key":"10.1016\/j.yebeh.2019.106839_bb0135","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2019.106839_bb0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","article-title":"Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease","volume":"95","author":"Yi","year":"2017","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.yebeh.2019.106839_bb0145","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/glia.23463","article-title":"Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora disease","volume":"66","author":"Auge","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.yebeh.2019.106839_bb0150","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.cmet.2019.08.014","article-title":"Nuclear glycogenolysis modulates histone acetylation in human non-small cell lung cancers","volume":"30","author":"Sun","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.yebeh.2019.106839_bb0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-030-27480-1_2","article-title":"Brain glycogen structure and its associated proteins: past, present and future","volume":"23","author":"Brewer","year":"2019","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.yebeh.2019.106839_bb0160","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/jcm8020246","article-title":"Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma (GRCC) of the breast in the U.S. population","volume":"8","author":"Zhou","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.yebeh.2019.106839_bb0165","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/hmg\/ddy044","article-title":"Astrocytes: new players in progressive myoclonus epilepsy of Lafora type","volume":"27","author":"Rubio-Villena","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.yebeh.2019.106839_bb0170","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1084\/jem.20141130","article-title":"Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia","volume":"212","author":"Boisson","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.yebeh.2019.106839_bb0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/nan.12171","article-title":"Familial polyglucosan body myopathy with unusual phenotype","volume":"41","author":"Fanin","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.yebeh.2019.106839_bb0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.mam.2015.08.006","article-title":"Polyglucosan storage myopathies","volume":"46","author":"Hedberg-Oldfors","year":"2015","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.yebeh.2019.106839_bb0185","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ana.23963","article-title":"Polyglucosan body myopathy caused by defective ubiquitin ligase RBCK1","volume":"74","author":"Nilsson","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2019.106839_bb0190","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.bbadis.2016.03.008","article-title":"Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease","volume":"1862","author":"Munoz-Ballester","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.yebeh.2019.106839_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.112959","article-title":"In vivo glutamate clearance defects in a mouse model of Lafora disease","volume":"320","author":"Munoz-Ballester","year":"2019","journal-title":"Exp Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019312661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019312661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:33:47Z","timestamp":1761503627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019312661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":39,"alternative-id":["S1525505019312661"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106839","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106839"}}